MEDICINE DETAILS
Inrebic
Active ingredient: Fedratinib
Inrebic is recorded in this directory with the active ingredient Fedratinib. This page brings together catalogue strength, dosage-form and pack records so they can be checked against a prescription.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Inrebic used for?
Inrebic (fedratinib) is used for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. The Food and Drug Administration’s (FDA) approval of Inrebic (fedratinib) was based on the results of a clinical trial where 289 patients with myelofibrosis were randomized to receive two different doses (400 mg or 500 mg daily by mouth) of Inrebic (fedratinib) or placebo.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Inrebic identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
100 mg · 120 capsules Catalogue organisation: Bristol-Myers Squibb GmbH & Co. KGaA
OFFICIAL SOURCES
Check the Inrebic record at an official source.
Search for “Inrebic” or “Fedratinib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Inrebic.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Inrebic
01What is Inrebic?＋
This directory record associates the brand name Inrebic with the active ingredient Fedratinib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Inrebic strengths and packs are recorded?＋
The catalogue currently shows: 100 mg · 120 capsules. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Inrebic?＋
Catalogue records currently name: Bristol-Myers Squibb GmbH & Co. KGaA. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Inrebic?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Inrebic, payment request, stock guarantee or binding offer.
06Can I buy Inrebic from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.